Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ: ALVO )

11.96 -0.03 (-0.25%)
Streaming Delayed Price Updated: 11:29 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alvotech - Ordinary Shares

< Previous 1 2 3 4 5 6 7 Next >
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT03, a Proposed Biosimilar for Prolia® and Xgeva®
From Alvotech
Via GlobeNewswire
3 mid-caps under $20 that Wall Street loves
MarketBeat's Stock Screener tool helped identify these three mid-cap stocks - with very bullish Wall Street sentiment - that are currently under $20 per share 
Via MarketBeat
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Alvotech Provides Update on Status of Biologics License Applications for AVT02 and AVT04
From Alvotech
Via GlobeNewswire
Alvotech's Earnings: A Preview
Via Benzinga
STADA and Alvotech secure approval for Uzpruvo, Europe’s first ustekinumab biosimilar to Stelara
From Alvotech
Via GlobeNewswire
Alvotech Clinical Study Results Demonstrate Therapeutic Equivalence between Biosimilar Candidate AVT06 and Reference Product Eylea® (aflibercept)
From Alvotech
Via GlobeNewswire
Alvotech Announces Positive Top-Line Results from a Pharmacokinetic Study for AVT05, a Proposed Biosimilar for Simponi® and Simponi Aria®
The study, assessing pharmacokinetics, safety, and tolerability of AVT05 compared to Simponi® (golimumab) in healthy adult subjects, met its primary endpoint 
From Alvotech
Via GlobeNewswire
Alvotech Reports Financial Results for First Nine Months of 2023 and Provides a Business Update
From Alvotech
Via GlobeNewswire
Earnings Scheduled For November 28, 2023
Companies Reporting Before The Bell • Elbit Systems (NASDAQ:ESLT) is projected to report quarterly earnings at $1.70 per share on revenue of $1.45 billion. 
Via Benzinga
Alvotech to Report Financial Results for the First Nine Months of 2023 on November 28, 2023, and Host Business Update Conference Call on November 29, 2023, at 8:00 am ET
From Alvotech
Via GlobeNewswire
Alvotech and JAMP Pharma Announce Receipt of Marketing Authorization for Jamteki™ (AVT04), the First Biosimilar of Stelara® (ustekinumab)
From Alvotech
Via GlobeNewswire
STADA and Alvotech receive positive CHMP opinion for Europe’s first ustekinumab biosimilar to Stelara
From Alvotech
Via GlobeNewswire
Alvotech to Present at the Jefferies 2023 London Healthcare Conference
From Alvotech
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For October 20, 2023
Via Benzinga
Alvotech Provides Update on Status of U.S. Biologics License Application for AVT04
From Alvotech
Via GlobeNewswire
Kashiv BioSciences Enters into Exclusive Licensing Agreement with Alvotech for Development & Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
From Kashiv Biosciences LLC
Via Business Wire
Alvotech Enters into Exclusive Licensing Agreement with Kashiv BioSciences for Development and Commercialization of a Proposed Biosimilar to Xolair® (omalizumab)
From Alvotech
Via GlobeNewswire
Alvotech Announces Approval in Japan of AVT04 (ustekinumab), a Biosimilar to Stelara®
From Alvotech
Via GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For September 21, 2023
Via Benzinga
Alvotech Provides U.S. Regulatory Update on AVT02, a High-Concentration Interchangeable Biosimilar Candidate to Humira® (adalimumab)
From Alvotech
Via GlobeNewswire
Alvotech Announces Changes to the Leadership Team
From Alvotech
Via GlobeNewswire
Alvotech Reports Financial Results for First Six Months of 2023 and Provides Business Update
From Alvotech
Via GlobeNewswire
Earnings Scheduled For August 30, 2023
Companies Reporting Before The Bell • Gaotu Techedu (NYSE:GOTU) is expected to report earnings for its second quarter. 
Via Benzinga
Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) in Egypt
- Approval of Adalimumab-EVA™ represents the second biosimilar approval under the strategic partnership between Alvotech and Bioventure 
From Alvotech
Via GlobeNewswire
Alvotech to Report Financial Results for the First Half of 2023 on August 30, 2023, and Host Business Update Conference Call on August 31, 2023, at 8:00 am ET
From Alvotech
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Alvotech, and FMC and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Alvotech, and Sanmina and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Bragar Eagel & Squire, P.C. Is Investigating Xponential, Franchise Group, Alvotech, and Sanmina and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
Alvotech Completes $100 Million Convertible Bond Private Placement
From Alvotech
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.